Cited 0 times in
Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박미성 | - |
dc.date.accessioned | 2015-12-24T09:43:44Z | - |
dc.date.available | 2015-12-24T09:43:44Z | - |
dc.date.issued | 2013 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/136423 | - |
dc.description | Dept. of Medicine/석사 | - |
dc.description.abstract | BACKGROUND: The incidence of multidrug-resistant (MDR)-chronic hepatitis B (CHB) during sequential lamivudine (LAM) and adefovir dipivoxil (ADV) treatment is increasing. We investigated the antiviral efficacies of various rescue regimens in patients who failed sequential LAM-ADV treatment.METHODS: A total of 48 patients (83.3% HBeAg-positive) who failed sequential LAM-ADV treatment were treated with one of the following regimens: entecavir (ETV) 1mg monotherapy (n=16), LAM+ADV combination therapy (n=20), or ETV(1mg)+ADV combination therapy (n=12). All patients had confirmed genotypic resistance to both LAM and ADV. Patients were evaluated every 12 weeks. RESULTS: There was no significant difference in the baseline characteristics and treatment duration among study groups. During treatments (median duration: 100 weeks), the decline of serum HBV DNA from baseline tended to be greatest in the ETV+ADV group at all-time points (week 48: -2.55 log10IU/ml, week 96: -4.27 log10IU/ml), but there was no statistical significance. The ETV+ADV group tended to have higher virologic response rates at 96 weeks compared to the ETV monotherapy or LAM+ADV groups (40.0% vs. 20.0% or 20.0%, p=0.656) and less virologic breakthrough was observed compared to the ETV monotherapy or LAM+ADV groups (8.3% vs. 37.5% or 30.0%, p=0.219), but there were no statistical significances. HBeAg loss occurred in one patient in the ETV+ADV group, two in the ETV monotherapy group, and none in the LAM+ADV group. Safety profiles were similar between each arm.CONCLUSIONS: ETV+ADV combination therapy tended to have a better antiviral efficacy compared to LAM+ADV or ETV monotherapy for MDR-CHB in Korea, where tenofovir is not yet available. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.publisher | Graduate School, Yonsei University | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B | - |
dc.title.alternative | 다약제 내성 만성 B형 간염 환자에서 항바이러스 병합 치료의 효과 | - |
dc.type | Thesis | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.localId | A01462 | - |
dc.identifier.url | https://ymlib.yonsei.ac.kr/catalog/search/book-detail/?cid=CAT000000139420 | - |
dc.contributor.alternativeName | Park, Mi Sung | - |
dc.contributor.affiliatedAuthor | 박미성 | - |
dc.type.local | Thesis | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.